Prevalence of resistant hypertension and associated factors in Japanese subjects with type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 110, Issue 1, 2015, Pages 18-25

  Yokoyama, H ^a   Araki, S ^b   Watanabe, S ^a   Honjo, J ^a,c   Okizaki, S ^a,d   Yamada, D ^a   Shudo, R ^a   Shimizu, H ^a   Sone, H ^a,e   Haneda, M ^c  

^a Jiyugaoka Medical Clinic   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c ASAHIKAWA MEDICAL COLLEGE   (Japan)

^d KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NIIGATA UNIVERSITY   (Japan)

Author keywords

Prevalence; Resistant hypertension; Risk factors; Therapeutics; Type 2 diabetes mellitus

Indexed keywords

ANTIHYPERTENSIVE AGENT; TRIACYLGLYCEROL;

AGE; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; JAPANESE (PEOPLE); MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PREVALENCE; PRIMARY MEDICAL CARE; RESISTANT HYPERTENSION; RETINOPATHY; SYSTOLIC BLOOD PRESSURE; ADULT; ALBUMINURIA; BLOOD PRESSURE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS, TYPE 2; DRUG RESISTANCE; HYPERTENSION; JAPAN; MIDDLE AGED; PHYSIOLOGY; RISK FACTOR;

ADULT; AGED; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DRUG RESISTANCE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; JAPAN; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS;

EID: 84943198693     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2015.08.007     Document Type: Article

References (37)

1. Reboldi G., Gentile G., Manfreda V.M., Angeli F., Verdecchia P. Tight blood pressure control in diabetes: evidence-based review of treatment targets in patients with diabetes. Curr Cardiol Rep 2012, 14:89-96.
2. Vijan S., Hayward R.A. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 2003, 138:593-602.
3. Ferrannini E1, Cushman W.C. Diabetes and hypertension: the bad companions. Lancet 2012, 380:601-610.
4. Sehestedt T., Hansen T.W., Li Y., Richart T., Boggia J., Kikuya M., Thijs L., et al. Are blood pressure and diabetes additive or synergistic risk factors? Outcome in 8494 subjects randomly recruited from 10 populations. Hypertens Res 2011, 34:714-721.
5. Egan B.M., Zhao Y., Brzezinski W.A. Epidemiology of hypertension in diabetes. Diabetes and Hypertension: Evaluation and Management 2012, 1-14. Springer Science+Business Media, New York. S.I. McFarlane, G.L. Bakris (Eds.).
6. Calhoun D.A., Jones D., Textor S., Goff D.C., Murphy T.P., Toto R.D., et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008, 51:1403-1419.
7. Fagard R.H. Resistant hypertension. Heart 2012, 98:254-261.
8. Persell S.D. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011, 57:1076-1080.
9. De la Sierra A., Segura J., Banegas J.R., Gorostidi M., de la Cruz J.J., Armario P., et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011, 57:898-902.
10. Oliveras A., de la Sierra A. Resistant hypertension: patient characteristics, risk factors, co-morbidities and outcomes. J Hum Hypertens 2014, 28:213-217.
11. Egan B.M., Zhao Y., Axon R.N., Brzezinski W.A., Ferdinand K.C. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011, 124:1046-1058.
12. Pimenta E., Calhoun D.A. Resistant hypertension: incidence, prevalence, and prognosis. Circulation 2012, 125:1594-1596.
13. Daugherty SL1, Powers J.D., Magid D.J., Tavel H.M., Masoudi F.A., Margolis K.L., et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012, 125:1635-1642.
14. Elliot W.J. Is fixed combination therapy appropriate for initial hypertension treatment?. Curr Hypertens Rep 2002, 4:278-285.
15. De Nicola L., Gabbai F.B., Agarwal R., Chiodini P., Borrelli S., Bellizzi V., et al. Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol 2013, 61:2461-2467.
16. Yokoyama H., Tomonaga O., Hirayama M., Ishii A., Takeda M., Babazono T., et al. Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. Diabetologia 1997, 40:405-411.
17. Kumar R., Sharma R.K., Agarwal S. Genetic predisposition for development of nephropathy in type 2 diabetes mellitus. Biochem Genet 2013, 51:865-875.
18. Pezzolesi M.G., Krolewski A.S. The genetic risk of kidney disease in type 2 diabetes. Med Clin N Am 2013, 97:91-107.
19. Yokoyama H., Kawai K., Ohishi M., Sone H., Japan Diabetes Data Management Study Group Familial predisposition to cardiovascular risk and disease contributes to cardiovascular risk and disease interacting with other cardiovascular risk factors in diabetes: implication for common soil (JDDM 14). Atherosclerosis 2008, 201. 332-328.
20. Shimamoto K., Ando K., Fujita T., Hasebe N., Higaki J., Horiuchi M., et al. Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 2014, 37:253-387.
21. James P.A., Oparil S., Carter B.L., Cushman W.C., Dennison-Himmelfarb C., Handler J., et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). J Am Med Assoc 2014, 311:507-520.
22. Matsuo S., Imai E., Horio M. Collaborators developing the Japanese equation for estimated GFR Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009, 53:982-992.
23. De la Sierra A1, Banegas J.R., Oliveras A., Gorostidi M., Segura J., de la Cruz J.J., et al. Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs. J Hypertens 2012, 30:1211-1216.
24. Solini A., Zoppini G., Orsi E., Fondelli C., Trevisan R., Vedovato M., et al. Resistant hypertension in patients with type 2 diabetes: clinical correlates and association with complications. J Hypertens 2014, 32:2401-2410.
25. Lithovius R., Harjutsalo V., Forsblom C., Saraheimo M., Groop P.H., FinnDiane Study Group Antihypertensive treatment and resistant hypertension in patients with type 1 diabetes by stages of diabetic nephropathy. Diabetes Care 2014, 37:709-717.
26. Calhoun D.A., Booth J.N., Oparil S., Irvin M.R., Shimbo D., Lackland D.T., et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension 2014, 63:451-458.
27. Hsieh Y.T., Tu S.T., Cho T.J., Chang S.J., Chen J.F., Hsieh M.C. Visit-to-visit variability in blood pressure strongly predicts all-cause mortality in patients with type 2 diabetes: a 5·5-year prospective analysis. Eur J Clin Invest 2012, 42:245-253.
28. Johansson J.K., Niiranen T.J., Puukka P.J., Jula A.M. Prognostic value of the variability in home-measured blood pressure and heart rate: the Finn-Home Study. Hypertension 2012, 59:212-218.
29. Kikkawa R1, Araki S., Haneda M., Kajiwara N., Hidaka H., Shigeta Y. Hypertension and the development of complications in patients with non-insulin dependent diabetes mellitus in Japan. J Am Soc Nephrol 1992, 3(Suppl. 4):S120-S125.
30. Fogarty D.G., Krolewski A.S. Genetic susceptibility and the role of hypertension in diabetic nephropathy. Curr Opin Nephrol Hypertens 1997, 6:184-191.
31. Rudnicki M., Mayer G. Significance of genetic polymorphisms of the renin-angiotensin-aldosterone system in cardiovascular and renal disease. Pharmacogenomics 2009, 10:463-476.
32. Tanner R.M., Calhoun D.A., Bell E.K., Bowling C.B., Gutiérrez O.M., Irvin M.R., et al. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol 2013, 8:1583-1590.
33. Oxlund C.S., Henriksen J.E., Tarnow L., Schousboe K., Gram J., Jacobsen I.A. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens 2013, 31:2094-2102.
34. Václavík J., Sedlák R., Plachy M., Navrátil K., Plásek J., Jarkovsky J., Václavík T., et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011, 57:1069-1075.
35. Fukuhara M., Arima H., Ninomiya T., Hata J., Hirakawa Y., Doi Y., et al. White-coat and masked hypertension are associated with carotid atherosclerosis in a general population: the Hisayama study. Stroke 2013, 44:1512-1517.
36. Franklin S.S., Thijs L., Li Y., Hansen T.W., Boggia J., Liu Y., et al. International database on ambulatory blood pressure in relation to cardiovascular outcomes investigators masked hypertension in diabetes mellitus: treatment implications for clinical practice. Hypertension 2013, 61:964-971.
37. Calhoun D.A. Hyperaldosteronism as a common cause of resistant hypertension. Annu Rev Med 2013, 64:233-247.